International Journal of Trend in Scientific Research and Development (IJTSRD)
Volume 6 Issue 3, March-April 2022 Available Online: www.ijtsrd.com e-ISSN: 2456 – 6470

Nanosponge: Leveraging Novel Technology

Radhika Kotame, Gayatri Wagh, Ehtesham Ansari

Assistant Professor, Matoshri Institute of Pharmacy, Dhanore, Maharashtra, India

ABSTRACT

The effective system of targeted drug delivery has been a dream for a long time, yet it is deeply irritated by the complex chemical involved in the development of the latest systems. The advanced drug delivery system has a number of problems such as poor skin tone, skin irritation, allergies and more. The biggest problems for improved chemical companies are their poor melting of water and pharmacy problems. These water-soluble drugs show few problems in combining them with a non-perishable variety and therefore the main problems associated with them are their very low bioavailability. The development of nanosponges has been a major step forward in overcoming these problems. Nanosponges are a novel class of colloidal structures based on hyper-crosslinked polymer consisting of solid colloidal nanoparticles and nanosized holes. These colloidal carriers with nano-size were recently developed and proposed for drug delivery, as their use can dissolve soluble drugs in the water and provide long-term release and improve drug availability by altering pharmacokinetic parameters of actives. . The development of nanosponges as drug delivery systems, with special reference to cyclodextrin-based nanosponges, is presented in this article. In the current review, attempts have been made to show the characteristics of cyclodextrin based on nanosponges and their applications in drug formation. The main focus is on discussing preparation methods, character separation methods and the use of these novel drug delivery carriers for therapeutic purposes.

KEYWORDS: *Nanosponge, poorsolubility, polymers, Medical, Formulations*

How to cite this paper: Radhika Kotame | Gayatri Wagh | Ehtesham Ansari "Nanosponge: Leveraging Novel Technology" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-6 | Issue-3, April 2022, pp.836-847, URL: www.ijtsrd.com/papers/ijtsrd49469.pdf

IJTSRD49469

INTRODUCTION

Nanosponges are a novel class of hyper-crosslinked polymer based colloidal structures consisting of solid colloidal nanoparticles and nanosized holes. Good-

- Known examples of nanosponge nanosponges based on titanium (1), silicon nano-sponge particles (2), hyper-crosslinked polystyrene nanosponges (3) and cyclodextrin-supported nanosponges (4).

An important attraction of nanosponge technology stems from the difficulty that has been encountered in the general structure in extracting active ingredients over time. Higher focus compared to shorter duration of action are common features of skin and personal care products. This can lead to a short-term drinking cycle followed by prolonged neglect. Side effects such as rashes or other serious side effects (due to the active ingredient penetrating the skin) are a major barrier to those skin and personal care products. Thus another technology that overcame these barriers was the need for an hour. In recent decades, nanoparticles as drug delivery systems have received a lot of attention. Nanotechnology even allows for the continuous release of active substances, compounds and agents, reducing irritation while maintaining efficiency, thus making nanoparticles a flexible vehicle for drug delivery (5, 6). However, only a few nanopreparations, such as abraxane, have reached the market (7). Proteins, peptides, genes, anti-cancer agents and biomolekules are loaded into nanoparticulate delivery systems and thoroughly researched to reduce adverse effects and improve efficiency (8-10). Nano particles provide a controlled release of bound drugs and during this action provide protection against drug particles in physical conditions that maintain the bioactivity of the compound. Nanoparticles can be used to make drugs in the liver, spleen and lungs as they are easily

absorbed by the macrophage system (11-15). Coats made of nanoparticles help to overcome the reticulo-endothelial detection of nanoparticles and thus bring the drug to various body systems such as BBB (16). Therefore, the benefits of nano-particulate drug delivery systems include bound drug protection, improved performance, reduced side effects, controlled release and drug identification. Nanoparticles come in the form of polymeric nanoparticles, solid lipid nanoparticles, nanoemulsions, nanosponges, carbon nanotubes, micellar systems, dendrimers, etc. Among these, nanosponge (NS) looks like a three-dimensional scaffold with a long polymer. spine. The polymer in the solution state is made up of small molecules called crosslinkers that act as small holding hooks to hold different parts of the polymer together. The result is the formation of circular particles with hydrophobic holes in which drug molecules can be trapped (17). A single nanosponge system contains a large number of voids connected within a fixed structure that can hold a variety of objects. The surface is usually porous, allowing for continuous flow of particles without particles (18). These nano-colloidal carriers were recently proposed for drug delivery, as their use can dissolve soluble drugs in the water and provide long-term release, as well as improve drug drug availability by altering pharmacokinetic parameters of active ingredients (19).

Identifying drug delivery has long been a study therapy - how to put them in the right place within the body and how to control drug delivery to eliminate the intended drug overdose of drug delivery programs has been a dream for a very long time. yet however it is very irritated by the complex chemistry connected [20 - 23]. The development of nanosponges is a chemical with holes integrated delivery systems are small circular particles with large porous surfaces. This is used for the flexible administration of cosmetic agents on the skin where by obtaining large edges such as a reduction in total volume, the maintenance of a permanent volume in the skin and the prevention of normal absorption. These nanosponges are often successfully included in the program for long-term non-binding and skin care topics thus reducing the variability of drug absorption, toxicity and increasing patient compliance by increasing the frequency intervals.

The .nanosponge is a new layer of fabric and is composed of tiny particles with a few wide holes in the nanometer, where a type of material is usually covered. These particles are able to carry each oleophilic and deliquescent material and increase the dissolution of water-soluble molecules. (24,25)



Fig1. Structure of Nanosponges



Nanosponges include a variety of Nanoparticles that incorporate drug molecules within their spinal cord through the process of coagulation, Nanoparticles are often divided into synthetic Nanoparticles and synthetic Nanoparticles. The primary type is represented by a nanosponge-like nanoparticles that contain a few holes that carry drug molecules. Poly nanocapsules (isobutyl-cyanoacrylate) (IBCA) also include Nanoparticles. They will attach to the drug molecules in their aquous environment. The second class consists of Nanoparticles, which bind to drugs with covakent bonds [4]. Nanosponges are able to provide solutions to many problems connected to the mold. Due to their small size and hollow environment they will bind the insoluble drug within the matrix and improve their bioavailability. They can bind drugs that do not dissolve within the matrix and improve their bioavailability. (26) They will be designed to direct drugs to specific areas, prevent drug and supermolecule deterioration and increase drug resistance in a highly controlled manner. Nanosponge is found in an efficient way of co-ordinating and interacting with living and non-living things. (27)

Advantages of nanosponge based drug delivery systems

- This technology offers entrapment of ingredients and reduces side effects;

- Improved stability, increased elegance and enhanced formulation flexibility;
- Extended release with continuous action up to 12–24 hours;
- Incorporation of immiscible liquids is possible;
- Improved material processing since liquids may be converted to powders.

Disadvantages

- Nanosponges comprise only small molecules [28]
- Rely only on uploads.

Characteristic features of nanosponges

- Nanosponges (1 µm or less) have a flexible polarity of holes. Nanosponges of a certain size and adjustable polarity can be assembled by alternating a crosslinker with a polymer component (29).
- They can be para-crystalline or crystalline form, depending on the process. The crystal formation of nanosponges plays a very important role in their synthesis with the drug. The drug loading capacity of nanosponges depends largely on the degree of polishing. Para-crystalline nanosponges have shown a wide range of drug loading properties (30).
- They are non-toxic, particles with insoluble holes in many natural solvents and are stable at temperatures up to 300 ° C (31).
- Nanosponges as a structure are stable over a pH range of 1 to 11 and a temperature of up to 130 ° C (36).
- They form a clear and opalescent suspension in water and can be reconstituted by dissolving heat, dissolving solvents, using microwaves and ultrasounds (32).

Sabo Their 3D architecture allows for the capture, transport and release of a wide variety of objects. They can be redirected to different sites due to their ability to connect with different working groups. Chemical bonds enable nanosponges to bind to the target surface. They form complex and implanted complexes with different drugs (22). Magnetic properties can be transferred to nanosponges (by adding magnetic particles to the reaction mixture).

Chemical used for synthesis of Nanosponges:-

Polymers	Hyper cross linked Polystyrenes, Cyclodextrins and its derivatives like Methyl β-Cyclodextrin, Alkyloxycarbonyl-Cyclodextrins, 2- Hydroxy Propyl β-Cyclodextrins and Copolymers like Poly (valerolactone -allylvalerolactone), Poly (valerolactone- allylvalerolactoneoxepane-dione), Ethyl Cellulose and PVA
Apolar solvents	Ethanol, Dimethylacetamide, Dimethyl formamide
Cross-linkers	Diphenyl Carbonate, Diarylcarbonates, Di-Isocyanates, Pyromellitic anhydride, Carbonyl-di-Imidazoles, Epichloridrine, Glutarldehyde, Carboxylic acid dianhydrides, 2,2-bis(acrylamido) Acetic acid and Dichloromethan.

Factors influencing the formation of nanosponges (33)

1) Polymers and crosslinkers. - The type of polymer used can affect the formation and performance of nanosponges. Effective crosslinkers convert nano-cavities molecules into three-dimensional, nanoporous structures. By adjusting the crosslinking rate, hydrophilic or hydrophobic components that can hold the target compounds are formed. Depending on the nature of the crosslinkers, nano-sponge structures that are soluble or insoluble are formed.

Hydrophilic nanosponges are formed when epichlorohydrin (24) is used as a crosslinker. Hydrophilic nanosponges can change the rate of drug release, and can be used to improve drug absorption across all biological barriers, acting as a potent drug carrier even in fast-release products. Hydrophobic nanosponges can be synthesized using diphenylcarbonate (4, 19, 20, 28, 29, 34) or pyromellitic anhydride (32), disocyanates (31, 55), carbonyldiimidazoles (19, 30, 35) and may serve as crosslinkers. - Storage carriers of water-soluble drugs including peptide and protein drugs (20). A list of polymers with their applications is given in Table I.

In addition to the nature of the polymer and crosslinker, the type of solvent and solvent medium used in the preparation process affects the formation of nanosponges.

2) Types of drugs and location used for communication. - Drug molecules to be combined with nanosponges must have certain characteristics in order to be effectively absorbed into nanosponges. Molecules with a molecular weight of between 100 and 400 Da and a ring of less than five can easily be trapped in the nanocavity of sponges. Also, these molecules should be less than 10 mg mL – 1 dissolved in water and the melting point should be below 250 ° C (23). Compounds with high melting points do not have high fixed values when loaded with nanosponges. Therefore, stable complexes

between drugs and nanosponges are not available when loaded into a tree. Drug loading is also affected if the drug has a high melting point. Low load of the tree can be seen with compounds dissolving at high temperatures. These low loading rates may be calculated due to the strength of the composite structure. The interaction between NS pits and target compounds depends largely on the content; that is, the hydrophilic medium will drive molecules of living visitors into hydrophobic holes, while the organic solvent tends to release organic molecules trapped in nanosponges. This strong attraction between host and visitor molecules depends on improved chemical and physical interactions such as matching polarity, size, hydrophobic environment and structural properties (34).

3) Complex temperature. - The stability of the complex depends on the temperature change. Consistent stability and temperature rise are associated with the opposite.In increasing temperatures, the apparent magnitude of the constant decrease decreases due to the reduction of drug / nanosponge interactions (35,36). Therefore, complete temperature control should be maintained when preparing nanosponges.

4) Replacement qualifications. - The type, number and position of the substitute in the polymeric molecule affects the complex ability of nanosponges (26). The type of replacement is important because the b-CD output is available in a variety of different ways to the active groups present on the surface of the cyclodextrin output. When compiled with the help of crosslinker, different functional groups can produce different types of complex substances (b-CD nanosponges, CD-carbamate nanosponges, CD-carbonate nanosponges, etc.)

There is a direct relationship between the available exchange rate and the link level. The higher the number of substitutes, the greater the likelihood that there will be a high affinity. A higher degree of bonding will produce more perforated nanosponges due to the increased interaction between the polymers forming a mesh-type network.

The position of the switch depends on the production conditions. A change in the production process will produce elements with different physicochemical properties due to the localization of a different functional group in the parent combination. For example, when produced under different conditions, the physicochemical properties of HP-b-CD samples with the same rate of conversion may differ due to the possible residence of hydroxypropyl groups in different positions in the parent CD molecule. Material purity can therefore have a significant impact on the final quality of nanosponges, indicating the importance of the polymer transformation rate.

As mentioned above, the type of polymer determines the type of nanosponges that can be synthesized. Thus, based on the polymer used, different types of nanosponges can be developed. The above factors should be considered during the production of nanosponges. A few well-known examples of nanosponges are titanium-based nanosponges (1), silicon nanosponge particles (2), hyper-crosslinked polystyrene nanosponges (3) and cyclodextrin-based nanosponges (4). Among the various types of nanosponges, cyclodextrin-based nanosponges have received extensive attention and are widely studied. In addition, this review focuses on cyclodextrin-based nanosponges for therapeutic use.

Classification of Nanosponge

Nanosponge is a type of Nanoparticles that binds molecules of drugs within their nucleus. By way of drug synthesis, Nanoparticles can be classified as follows:

1. Ecapsulating Nanoparticles: - This type is represented by nanosponge and nanopartilces. Nanosponges are similar to alginate nanosponges, which are sponges like nano particles with multiple holes that carry drug molecules in their aqueous root (37,38)
2. Complex Nanoparticles: - This type of Nanoparticles pulls molecules by charging electrostatics.
3. Conjugating Nanoparticles: - This type of Nanoparticles binds to drugs through binding bonds. Unlike other Nanoparticles, they are insoluble in water and organic solvent, thin, non-toxic and stable at high temperatures up to 300ºC.

METHODOLOGY FOR PREPARATION OF THE NANOSPONGES:

The various methods used for the preparation of Nanosponges are given below:

1. SOLVENT DIFFUSION METHODS.
2. ULTRASOUND ASSISTED SYNTHESIS.
3. NANOSPONGES PREPARED FROM HYPER CROSS LINKED CYCLODEXTRIN.
4. SOLVENT METHOD.
5. LOADING OF DRUG INTO NANOSPONGE.

1. SOLVENT DIFFUSION METHODS [39-41]

A. Distribution of Quassi emulsion solvent:

The polymer is soluble in a suitable solvent (internal phase). The drug can be added to the solution and dispersed under ultrasonication at 35ºC. The inner layer is poured into a polyvinyl alcohol solution in water after 60 minutes of stirring, the mixture is filtered. Then the prepared nanosponges will be dried in an oven heated at 40ºC for 12 hours.

B. Emulsion solvent dispersion method:

for the preparation of the aqueous phase and the organic phase, the aqueous phase contains the copolymer and the organic phase contains the drug and the polymer. The Organic phase is gradually added to the liquid phase and is stirred for 2-3 hours at 1000rpm. Prepared nanosponge is filtered, washed, and then dried in air at room temperature or in a vacant oven for 40ºC for 24 hours.



2. ULTRASOUND ASSISTED SYNTHESIS[42-43]

The polymer is mixed with a cross linker with a balanced ratio on the flask. The flask is then placed in a water-filled ultrasound tub and the temperature is maintained at 90ºC. Sonicate the mixture for 5 hours. To remove the unresponsive polymer, the product is washed with water. Then the product is diluted with ethanol by removing the soxhlet .Allow the product to dry under a vacuum of 25ºC.



3. NANOSPONGES PREPARED FROM HYPER CROSS LINKED CYCLODEXTRIN

In this process cyclodextrin reacts with cross linkers such as di-isocianate, diaryl carbonates, carbonyl di-imidazoles etc. The size of the sponges is controlled according to the body, the congestion of excess charge attached to completely different molecules. Depending on the connector the nanosponges are assembled in a neutral or acidic manner. The ability of nanosponges to combine drugs with completely different properties and solubility. They are accustomed to the development of the soluble combination of a water soluble substance mainly BCS tree phase II [44].



4. SOLVENT METHOD

In this chemical reaction the mixture was mixed with an acceptable solvent, especially in the solvent aprotic solvent such as dimethylformamide, dimethylsulfoxide. This combination would add to the excess crosslinker value, ideally in a crosslinker / polymer molar quantitative relation of 4 to 16. The reaction is from a dole without temperatures ranging from 10ºC to solvent reflux temperature, a period that starts at 1-40 hours. , the most popular cross linkers are carbonyl compounds (dimethyl carbonate and carbonyl diimidazole) [28]. for sale. by filtering under vaccum and later in the sublimate by extracting the soxhlet for a long time with ethyl alcohol. Commodities are dried under vaccum and ground in a mortar to obtain a fine powder [45].



5. LOADING OF DRUG INTO NANOSPONGE

Nanosponges for drug delivery should be made in advance to obtain a particle size of less than 500nm. Nanosponges are suspended in water and sonicated to prevent the formation of aggregates and then centrifused suspension to obtain a fraction of the mixture. The supernatant was separated and dried by freezing of the sample [31]. The suspension of the nanosponge binary mixture was fine and distributed the remaining mass of the drug and ended up being suspended under constant motion for some time to become more complex. Once complex, the soluble (non-soluble) drug was separated from the complex drug by natural process. Solid crystals of

nanosponges are then obtained by evaporation of solvent or by freezing [30,31]. The crystalline structure of nanosponges plays a very important role in drug synthesis. Anecdotal evidence that paracrystalline nanosponges have shown a completely different loading capacity compared to pure nanosponges. Drug loading is larger with pure nanosponges and then single paracrystalline. In nanosponges with the wrong crystal, drug loading occurs as a mixture rather than a complex infusion [46].



MECHANISM OF DRUG RELEASE FROM NANOSPONGES

Since nanosponges have an open structure (surrounding nanosponges do not have a continuous membrane), an active element is added to the car by an associate-type type. The integrated component is ready to move freely from the particles into the car until the vehicle is fully loaded and thus equates. As soon as the product is applied to the skin, the vehicle containing the active ingredient receives impurities causing a disturbance within the balance. Thus, the flow of active substances from nanosponge particles to vehicles begins to coagulate until the vehile is absorbed or dried. Even when the retention of nanosponge particles on the surface of the skin i.e. the horn layer, the removal of the active substance persists on the skin for a long time.

CHARACTERIZATION OF NANOSPONGES:

1) Melting phase. - The impact of NSs on drug solubility is investigated by a phase solubility process (48). To determine the soluble components of the phase, the excess solvent is added to the appropriate solvents to obtain complete solutions. Fully drug overdose is treated with various concentrations of empty nanosponges, 1: 1, 1: 2, 1: 3, etc. As their concentration increases, more and more trees interact with NS. Research is done until equity is found. Drawing episode of NS concentration vs. drug concentration and type of structure is defined with the help of the Higuchi and Connors subdivision (49). Fixed fixed values give an idea of the degree of interaction between nanosponges and wood. Drug interactions with nanosponges can increase the solubility of solvents in the water and thus the degree of solubility. Such a study was performed with itraconazole loaded with cyclodextrin nanosponges prepared by Shankar et al. Therefore, nanosponges can significantly increase the solubility of molecules with very low water solubility such as anti-cancer drugs, steroids and anti-inflammatory drugs (47,48).



2) Interaction with the water level. - UV spectroscopy is used as a tool for researching the interaction of complete solutions. Increasing concentrations of nanosponge solutions (1– 80 ppm) are added to the concentrated concentrate of the tree. Samples were kept overnight to work and finally filtered solutions were screened for lmax and absorption was measured. Drug loading is interpreted by taking synthetic scans at UV radiation and analyzing changes in the maximum absorption rate in the spectra compared to pure drug (49).

3) Porosity - Porosity research is performed to test the quality of nanochannels and nanocavities formed. Porosity of nanosponges is tested with a helium pycnometer, as helium gas can penetrate into the internal and external channels of objects. The actual volume of the material is determined by the removal of helium (50). Due to their hollow nature, nanosponges show a higher smoothness compared to the parent polymer used to build the system.

Percentage of porosity is given by equation (1).

% Porosity (E) = Bulk Volume - Actual Volume ´ 100 (1)
Bulk volume

4) Average diameter and polydispersity indices of nanosponges - This is usually determined using particle size analysis using a dynamic light scattering

system (DLS) (also known as photon correlation spectroscopy, PCS) (51–59). With the help of the autocorrelation function, PCS correlates the variation in light intensity dispersed to component size (60). PCS / DLS measures hydrodynamic diameter, that is, it considers all subcutaneous particles to be circular. DLS / PCS provides particle size by taking into account the effective viscosity, temperature and refractive index of the dispersing medium. Therefore, the measured particle size will be the parameter obtained after considering all the factors. It is always preferred to have quality results as well. Particle quality analysis can be performed by scanning electron microscopy (SEM), transmission electron microscopy (TEM) or natural electron microscopy scanning (ESEM) sample analysis. Particle size and shape can be determined by dissolving the sample in water or other suitable solvents and further testing using techniques such as SEM / TEM / ESEM. For example, paclitaxel-loaded nanosponges were detected showing a distribution of mononodal particles of 350 ± 25 nm, with a small distribution (polydispersity index, p <0.2) (51).

5) Zeta Power - The Zeta strength of any system under investigation is a measure of local billing. Extra charging is a parameter that affects body distribution and interaction with the biological environment. Zeta-strength ratio includes consideration of electrical potential, i.e., diffusion coefficient and electrophoretic mobility (61). These values are converted to zeta power after calculations from the Smolu-chowski or Stokes equation calculations. PH and electrolyte concentration (62, 63) need to be considered when measuring zeta power. The stability of synthetic nanopa- ticles can be measured by the possible testing of zeta. Zeta power in water should be ± 30 mV, high enough to provide a stable nano suspension that does not mix over time. Cavalli et al. measure electrophoretic flow as well zeta power using 90 PLUS steel. To obtain zeta power, samples of nanosponge dispersions were diluted with KCl solution (0.1 mmol L – 1) and placed in an electrophoretic cell, where an electrical field of about 15 V / cm (52) was used.

6) SEM and TEM. - These tools are used to test particle size and size as described above (4) and to obtain morphological information related to the drug delivery system under investigation (64-72). SEM involves the transfer of flexibility in particles formed under a vacuum by a concentrated electron beam. Whenever wet samples are to be investigated, ESEM may be hired. TEM involves investigating the morphology of fixed particles in a liquid. TEM and SEM studies conducted by Ansari et al. prepared nanosponges. A TEM study conducted by these authors (53) revealed a typical circular shape and size of NS. The shape and size of the developed nano-sponges remained unaffected even after drug injection into the nanosponges.

7) Trans-infrared (FT-IR) spectroscopy. - It serves as a great tool for determining the existence of working groups. After polymer synthesis, the appearance of active clusters in the FT-IR spectrum is an indication of the formation of bonds between the two monomer units of the polymer. In the FTIR crystal structure, vibration spectrum is obtained (54). The FT-IR spectra of dried nanosponges, pure drugs and drug-laden nanosponges are taken to understand interactions. The spectra is found in the wavenumber range of 4000 to 650 cm-1. FT-IR also helps in determining the hydrophobic and hydrophilic components in the advanced system. Ansari et al. (35) performed a FTIR spectra comparison of resveratrol and complex and showed significant changes in the region of fingerprints, i.e., 900 to 1400 cm-1 showing drug loading on nanosponges.

8) Differential scanning calorimetry (DSC) - Thermo-analytical methods determine whether a drug object undergoes a certain change before the temperature drop of the improved delivery system. Changes in a substance may be in the form of melting, evaporation, decomposition, oxidation or polymorphic modification showing complex formation. The thermogram obtained by DTA and DSC can be monitored to expand, relocate and detect new peaks or the disappearance of certain peaks. The absence of a high melting point of the crystalline structure drug in the DSC thermogram is a sign of a dispersed molecule within the polymer. Changes in weight loss can also provide supporting evidence

Applications of nanosponges in pharmaceuticals

1) Development of drug stability- b-CD units bonded with polymer, where the number of b-CD units bound to the same polymer series. Several b-CD units increase the stability of the drug complex (64-66). In addition, the polymer may interact with b-CD components in strengthening structures. Such studies have been developed for proteins and peptides due to their insufficiency, high production capacity, immune system and immune response and poor bioavailability and sensitivity to protease (4). Bovine serum albumin (BSA) soluble proteins are unstable, stored in a lyophilized state. However, proteins can be mutated at random in lyophilization and take on a completely different fusion in the native structure. A major factor in the formation and development of proteins is the need to maintain their natural composition during processing and long-term storage. In the nanosponge-

based system, BSA-like proteins are well incorporated into swellable cyclodextrin based poly (amidoamine) and nano sponges and increase their stability (67).

2) Nanosponges as carriers of biocatalysts in the delivery and release of enzymes, proteins, vaccines and antibodies. - Proteins, peptides, enzymes and their derivatives are used in the biomedical and therapeutic field. Proteolytic enzymes are used to treat cancer or a type of mucopolysaccharidosis, while DNA and oligonucleotides are used in gene therapy. The administration of these molecules presents various problems and limitations (79). Similar to protein protection and fitness concerns, there are concerns about the enzyme, the vaccine and the stability of the immune system. Proteins and other macromolecules can be transported and transported throughout the biological barrier, targeted at the site by advertising or incorporating them into cyclodextrin nanosponges.

3) Changing drug release. - Regular management is an important part of many common, available service delivery programs. However, the drug loaded on the nanosponge structure can be stored and released slowly over time. Hydrophilic CD NS can change the rate of drug release, which can be used to improve drug absorption across all biological barriers, acting as a potent drug carrier in the formation of rapid release. Hydrophobic CD NS may serve as a continuous carrier of water-soluble drugs, including peptide and protein-containing drugs (23). Nanosponges can also be used as carriers of drugs such as doxorubicin (an anti-cancer drug), and may protect the drug in the stomach. The drug is released very slowly at pH 1.1, and release is faster when the pH is raised to 7.4.

4) Successful delivery carriers. - Cyclodextrin nanosponges have been used as antitumor drugs such as paclitaxel, camptothecin and tamoxifen which present bioavailability problems because their solubility in water is low or nonexistent. The drugs were incorporated into nanosponges and experiments were performed on various cell lines to investigate their anti-inflammatory effect. Complications have shown a greater effect than that of the drug alone (19). The total bioavailability of paclitaxel increased after its loading on nanosponges and was found to be 2.5 times higher than in the empty drug (34). Econazole nitrate, an antifungal agent used topically to relieve symptoms of candidasis, dermatophytosis, versicolor and skin diseases, is available in creams, ointments, ointments and solutions. The incorporation of adsorption is not important when econazole nitrate is applied to the skin and therefore a high concentration of active agents is required for effective treatment. To overcome this problem, econazole nitrate nanosponges are synthesized in the form of an emulsion solvent and are loaded with hydrogels to form a local depot for continuous drug extraction (68,69).

5) Development of melting. - The presence of connecting holes and cyclodextrin in the structure tends to interact with active molecules. These elements cause a number of substances to be absorbed and dissolved in the built-up holes. Blending compounds or solid dispersion with CDs can improve drug solubility or the rate of dissolution of drugs that do not dissolve in water due to the reduction of drug crystals. The effect obscures most of the hydrophobic activity in the inner surface of the CD while the hydrophilic hydroxyl groups in the outer surface are always exposed to the surface; the complete effect is that a melt-based melt is formed (82). Among the various CDs available for sale, methylated CDs with the lowest molar substitution are the most potent solvents. CD nanosponges can greatly improve drug elimination even when they are not complicated. CD nanosponges may act as release enhancements; for example, b-CDs have been reported to improve the release rate of soluble drugs such as naproxen and ketoprofen (70).

CDs also increase hydrophobic drug penetration by increasing drug solubility and dissolution and thus making them available at the top of the biological barrier, where they break down into membranes without interfering with the lipid barriers of the barrier. The effect of CD nanosponges on drug-soluble dexa-methasone, flurbiprofen and doxorubicin hydrochloride, which have different properties and solubilities was investigated by Trotta et al. Dexamethasone and flurbiprofen are lipophilic drugs with P logs 1.9 and 4.1, respectively, while doxorubicin hydro-chloride is a hydrophilic drug with a P value of 0.25. The improved aqueous solubility of lipophilic drugs was compared with the hydrophilic drug doxorubicin after the drugs were loaded into nanosponges. This behavior may be attributed to the higher number of lipophilic sites available for lipophilic drug combinations compared to the hydrophilic sites on cyclodextrin. Marketed Formulations:

CONCLUSION:-

In addition to the points, it will be concluded that Nanosponges have a wide range of useful properties, can use a promising drug delivery tool economically, and may be considered a brand new carrier for skin delivery drugs and medical features. They provide a combination of individual lipotropic and deliquescent

drugs, as well as regulated patents in addition to the drug binding in the targeted area. Theeby increases bioavailability and performance. The level of particle size and the degree of non-corrosion required may be achieved by a combination of strong chemicals to exceed the bond size. In addition, Nanosponges are based primarily on the delivery system and protect the active moiety from damage. The small size and round shape of the delivery system allows for the formation of completely different value forms such as parerral, aerosol, topical and moreover as endless oral quantities as needed and advanced methods.

REFERANCE

[1] L. Guo, G. Gao, X. Liu and F. Liu, Preparation and characterization of TiO2 nanosponge, Mater. Chem. Phys. 111 (2008) 322–325; DOI:10.1186/1556-276X-6-551.

[2] D. Farrell, S. Limaye and S. Subramanian, Silicon Nanosponge Particles, U. S. Pat 0, 251, 561A1, 9 Nov 2006.

[3] V. Dakankov, M. Llyin, M. Tsyurupa, G. Timofeeva and L. Dubronina, From a dissolved poly- styrene coil to intramolecularly hyper cross linked nanosponges, Macromolecules 29 (1998) 8398– 8403; DOI: 10.1021/ma951673i.

[4] S. Swaminathan, L. Pastero, L. Serpe, F. Trotta, P. Vavia, D. Aquilano, M. Trotta, G. Zara and R. Cavalli, Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical char- acterization, stability and cytotoxicity, Eur. J. Pharm. Biopharm. 74 (2010) 193–201; DOI: 10.1016/ j.ejpb.2009.11.003.

[5] F. Melani, P. Mura, M. Adamo, F. Maestrelli, P. Gratteri and C. Bonaccini, New docking CFF91 parameters specific for cyclodextrin inclusion complexes, Chem. Phys. Lett. 370 (2003) 280–292; DOI:10.1016/S0009-2614(03)00126-X.

[6] P. Couvreur and C. Vauthier, Nanotechnology: intelligent design to treat complex disease, Pharm. Res. 23 (2006) 1417–1450; DOI:10.1007/s11095-006-0284-8.

[7] C. Zhang, N. Awasthi, M. A. Schwarz, S. Hinz and R. E. Schwarz, Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer, PLoS One. 8 (2013) e58037; DOI:10.1371/journal.pone.0058037.

[8] Y. Fukumori and H. Ichikawa, Nanoparticles for cancer therapy and diagnosis, Adv. Powder Technol. 17 (2006) 1–28; DOI:10.1163/156855206775123494.

[9] M. Morishita and N. Peppas, Is the oral route possible for peptide and protein drug delivery, Drug Discov. Today 11 (2006) 905–910; DOI:10.1007/s11095-006-0284-8.

[10] H. Cohen, R. Levy, J. Gao, I. Fishbein, V. Kousaev, S. Sosnowski, S. Slomkowski and G. Golomb, Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles, Gene Ther. 7 (2000) 1896–1905; DOI:10.1038/sj.gt.3301318.

[11] L. Grislain, P. Couvreur, V. Lenaerts, M. Roland, D. Deprez-Decampeneere and P. Speiser, Phar- macokinetics and distribution of a biodegradable drug-carrier, Int. J. Pharm. 15 (1983) 335–345; DOI:10.1016/0378-5173(83)90166-7.

[12] L. Illum, S. S. Davis, C. G. Wilson, N. W. Thomas, M. Frier and J. G. Hardy, Blood clearance and organ deposition of intravenously administered colloidal particles, The effects of particle size, nature and shape, Int. J. Pharm. 12 (1982) 135–146; DOI:10.1016/0378-5173(82)90113-2.

[13] P. Couvreur, B. Kante, V. Lenaerts, V. Scailteur, M. Roland and P. Speiser, Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles, J. Pharm. Sci. 69 (1980) 199–202; DOI:10.1002/jps.2600690222.

[14] J. Kreuter, Nanoparticles, in Encyclopedia of Pharmaceutical Technology (Ed. J. Swarbrick and J. C. Boylan), Marcel Dekker In., New York 1994, pp. 165–190.

[15] J. Xing, D. Zhang and T. Tan, Studies on the oridonin-loaded poly(D, L-lactic acid) nanoparti- cles in vitro and in vivo, Int. J. Biol. Macromol. 40 (2007) 153–158; DOI:10.1016/j.ijbiomac.2006.07.001.

[16] E. Garcia-Garcia, K. Andrieux, S. Gil and P. Couvreur, Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain, Int. J. Pharm. 298 (2005) 274–292; DOI:10.1016/j.ijpharm.2005.03.031.

[17] S. Subramanian, A. Singireddy, K. Krishnamoorthy and M. Rajappan, Nanosponges: A Novel Class of Drug Delivery System – Review, J. Pharm. Pharmac. Sci. 15 (2012) 103–111.

[18] A. Nokhodchi, M. Jelvehgari, M. Reza Siahi and M. Reza Mozafar, Factors affecting the mor- phology of benzoyl peroxide microsponges, Micron 38 (2007) 834–840, DOI: 10.1016/j.micron.2007.06.012.

[19] F. Trotta and R. Cavalli, Characterization and application of new hyper-cross-linked cyclo-dextrins, Compos. Interfaces 16 (2009) 39–48, DOI: 10.1163/156855408X379388.

[20] F. Trotta, R. Cavalli, V. Tumiatti, O. Zerbinati, C. Roggero and R. Vallero, Ultrasound Assisted Synthesis of Cyclodextrin Based Nanosponges, EP Pat 1786841A1, 23May, 2007.

[21] S. Eki, T. Lei, L. Jingquan, J. Zhongfan, B. Cyrille and P. D. Thomas, Biodegradable star poly- mers functionalized with b-cyclodextrin inclusion complexes, Biomacromolecules, 10 (2009) 2699– 2707; DOI:10.1021/bm900646g.

[22] S. Swaminathan, R. Cavalli, F. Trotta, P. Ferruti, E. Ranucci, I. Gerges, A. Manfredi, D. Marinotto and P. Vavia, In vitro release modulation and conformational stabilization of a model protein using swellable polyamidoamine nanosponges of b-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem. 68 (2010) 183–191; DOI:10.1007/s10847-010-9765-9.

[23] A. Vyas, S. Saraf and S. Saraf, Cyclodextrin based novel drug delivery systems, J. Incl. Phenom. Macrocycl. Chem. 62 (2008) 23–42; DOI: 10. 1007/s10847-008-9456-y.

[24] T. Girek and W. Ciesielski, Polymerization of b-cyclodextrin with maleic anhydride along with thermogravimetric study of polymers, J. Incl. Phenom. Macrocycl. Chem. (2010) 1–7; DOI: 10.1007/s10847-010-9778-4.

[25] D. Li and M. Ma, Nanosponges: From inclusion chemistry to water purifying technology, Chem. Sci. Technol. (1999) 26–28.

[26] C. Rajeswari, A. Alka, A. Javed and R. Khar, Cyclodextrins in drug delivery: an update review, AAPS PharmSciTech. 6 (2005) E329-E357; DOI: 10.1208/pt060243.

[27] A. Modi and P. Tayade, Comparative solubility enhancement profile of valdecoxib with differ-ent solubilization approaches, Ind. J. Pharm. Sci. 69 (2007) 427–430; DOI:10.4103/0250-474X.33156.

[28] R. Cavalli, F. Trotta and W. Tumiatti, Cyclodextrin-based nanosponges for drug delivery, J. Incl. Phenom. Macrocycl. Chem. 56 (2006) 209–213; DOI:10.1007/s10847-006-9085-2.

[29] F. Trotta, V. Tumiatti, R. Cavalli, C. Roggero, B. Mognetti and G. Berta, Cyclodextrin-based Nano- sponges as a Vehicle for Antitumoral Drugs, WO 2009/003656 A1; 2009.

[30] F. Trotta and T. Wander, Cross-linked Polymers Based on Cyclodextrins for Removing Polluting Agents, WO 2003/085002, US20050154198 A1, 14 July. 2005.

[31] S. Swaminathan, P. Vavia, F. Trotta and S. Torne, Formulation of beta-cyclodextrin based nano- sponges of Itraconazole, J. Incl. Phenom. Macrocycl. Chem. 57 (2007) 89–94; DOI:10.1007/s10847-006-9216-9.

[32] A. Mele, F. Castiglione, L. Malpezzi, F. Ganazzoli, G. Raffaini, F. Trotta, B. Rossi, A. Fontana and G. Giunchi, HR MAS NMR, powder XRD and Raman spectroscopy study of inclusion phenom- ena in b-CD nanosponges, J. Incl. Phenom. Macrocycl. Chem. 69 (2011) 403–409; DOI:10.1007/ s10847-010-9772-x.

[33] S. Swaminathan, P. Vavia, F. Trotta, R. Cavalli, P. Ferruti, E. Ranucci and I. Gerges, Release mod- ulation and conformational stabilization of a model protein by use of swellable nanosponges of b-cyclodextrin, First European Cyclodextrin Conference, Aalborg, Denmark 2009.

[34] S. Torne, K. Ansari, P. Vavia, F. Trotta and R. Cavalli, Enhanced oral bioavailability after admin- istration of paclitaxel-loaded nanosponges, Drug Deliv. 17 (2010) 419–425; DOI:10.3109/10717541003777233.

[35] K. Ansari, P. Vavia, F. Trotta and R. Cavalli, Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study, AAPS Pharm SciTech, 12 (2011) 279–286; DOI:10.1208/s12249-011-9584-3.

[36] E. Patel and R. Oswal, Nanosponge and micro sponges: a novel drug delivery system, Int. J. Res. Pharm. Chem. 2 (2012) 237–244.

[37] T. Loftsson and M. Brewster, Pharmaceutical applications of cyclodextrins: drug solubilization and stabilization, J. Pharm. Pharmacol. 85 (1996) 1017–1025; DOI:10.1021/js950534b.

[38] A. Radi and S. Eissa, Electrochemical study of indapamide and its complexation with b-cyclo-dextrin, J. Incl. Phenom. Macrocycl. Chem. 71 (2011) 95–102; DOI:10.1007/s10847-010.9906-1.

[39] H. Bricout, F. Hapiot, A. Ponchel, E. Monflier and S. Tilloy, Chemically modified cyclodextrins: an attractive class of

supramolecular hosts for the development of aqueous biphasic catalytic processes, Sustainability 1 (2009) 924–945; DOI:10.3390/su1040924.

[40] H. Dodziuk, Molecules with Holes – Cyclodextrins, in Cyclodextrins and Their Complexes (Ed. H. Dodziuk), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 2006, pp. 1–30.

[41] D. Li and M. Ma, Nanosponges for water purification, Clean Prod. Process. 2 (2000) 112–16; DOI:10.1007/s100980000061.

[42] E. Bilensoy and A. Atilla, Cyclodextrin-based Nanomaterials in Pharmaceutical Field, in Pharmaceuti- cal Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing, John Wiley & Sons Inc. Publishers 2010; DOI:10.1002/9780470259818.ch31.

[43] R. Lala, A. Thorat and C. Gargote, Current trends in b-cyclodextrin based drug delivery sys- tems, Int. J. Res. Ayur. Pharm, 2 (2011) 1520–1526.

[44] B. Mamba, R. Krause, T. Malefetse and S. Sithhole, Cyclodextrin nanosponges in the removal of organic matter to produce water for power generation, Water SA, 34 (2008) 657–660.

[45] B. Mamba, R. Krause, T. Malefetse, S. Mhlanga, S. Sithhole, K. Salipira and E. Nxumalo, Re- moval of geosmin and 2-methylisoborneol (2-MIB) in water from Zuikerbosch water treatment plant (Rand Water) using b-cyclodextrin polyurethane, Water SA, 32 (2007) 223–228.

[46] S. Tang, L. Kong, J. Ou, Y. Liu, X. Li and H. Zou, Application of cross-linked b-cyclodextrin polymer for adsorption of aromatic amino acid, J. Mol. Recogn. Macrocyclic Chem. 19 (2006) 39– 48; DOI: 10.1002/jmr.756.

[47] F. Trotta, R. Cavalli, S. Swaminathan, C. Sarzanini and P. Vavia, Novel functionalized nano- sponges: synthesis, characterization. Safety assessment, cytotoxicity testing and interaction stu- dies. Proceedings of the 14th International Cyclodextrin Symposium, Kyoto 2008, pp. 338–342.

[48] G. Yurtdas, M. Demirel and L. Genc, Inclusion complexes of fluconazole with b-cyclodextrin: physicochemical characterization and in vitro evaluation of its formulation, J. Incl. Phenom. Ma- crocycl. Chem. 70 (2011) 429–435; DOI:10.1007/s10847-010-9908-z.

[49] A. Rasheed, Cyclodextrins as drug carrier molecule: a review, Sci. Pharmac. 76 (2008) 567–598; DOI:10.3797/scipharm.0808-05.

[50] P. Sinko, Martin's Physical Pharmacy and Pharmaceutical Sciences, 5th ed., Lippincott Williams & Williams Publishers, Philadelphia 2006, p. 466.

[51] T. Govender, S. Stolnik, M. Garnett, L. Illum and S. Davis, PLGA nanoparticles prepared by na- noprecipitation: drug loading and release studies of a water soluble drug, J. Control. Release 57 (1999) 171–185; DOI:10.1016/S0168-3659(98)00116-3.

[52] S. Galindo-Rodriguez, E. Allémann, H. Fessi and E. Doelker, Physicochemical parameters asso- ciated with nanoparticle formation in the salting-out, emulsification-diffusion and nanoprecipi- tation methods, Pharm. Res. 21 (2004) 1428–1439; DOI:10.1023/B:PHAM.0000036917.75634.be.

[53] M. Leroueil-Le Verger, L. Fluckiger, Y. Kim, M. Hoffman and P. Maincent, Preparation and char- acterization of nanoparticles containing an antihypertensive agent, Eur. J. Pharm. Biopharm. 46 (1998) 137–143; DOI:10.1016/S0939-6411(98)00015-0.

[54] N. Santos-Magalhães, H. Fessi, F. Puisieux, S. Benita and M. Seiller, An in-vitro release kinetic examination and comparative evaluation between submicron emulsion and polylactic acid na- nocapsules of clofibride, J. Microencapsul. 12 (1995) 195–205; DOI:10.3109/02652049509015290.

[55] A. Layre, R. Gref, J. Richard, D. Requier, H. Chacun, M. Appel, A. Domb and P. Couvreur, Na- noencapsulation of a crystalline drug, Int. J. Pharm. 298 (2005) 323–327; DOI:10.1016/j.ijpharm.2005.02.039.

[56] D. Lemoine, C. Francois, F. Kedzierewicz, V. Preat, M. Hoffman and P. Maincent, Stability study of nanoparticles of poly(b-caprolactone), poly(D, L-lactide) and poly(D, L-lactideco-glycolide), Biomaterials 17 (1996) 2191–2197. DOI: 10.1016/0142-9612(96)00049-X.

[57] Y. Jeong, Y. Shim, C. Kim, G. Lim, K. Choi and C. Yoon, Effect of cryoprotectants on the recon- stitution properties of surfactant-free nanoparticles of poly (D, L-lactide-co-glycolide), J. Micro- encapsul. 22 (2005) 593–601; DOI:10.1080/02652040500162659.

[58] H. Redhead, S. Davis and L. Illum, Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer

407 and poloxamine 908: in vitro characterisation and in vivo evaluation, J. Control. Release, 70 (2001) 353–363; DOI:10.1016/S0168-3659(00)00367-9.

[59] M. Bivas-Benita, S. Romeijn, H. Junginger and G. Borchard, PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium, Eur. J. Pharm. Biopharm. 58 (2004) 1–6; DOI:10.1016/j.ejpb.2004.03.008.

[60] R. Pecora, Dynamic light scattering measurement of nanometer particles in liquids, J. Nanopar- ticle Res. 2 (2000) 123–131; DOI: 10. 1023/A:1010067107182.

[61] M. Santander-Ortega, A. Jódar-Reyes, N. Csabac, D. Bastos-González and J. Ortega-Vinuesa, Colloidal stability of Pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mecha- nisms, J. Colloid. Interf. Sci. 302 (2006) 522–529; DOI:10.1016/j.jcis.2006.07.031.

[62] Y. Ishikawa, Y. Katoh and H. Ohshima, Colloidal stability of aqueous polymeric dispersions: ef- fect of pH and salt concentration, Colloid Surf. B 42 (2005) 53–58; DOI:10.1016/j.colsurfb.2005.01.006.

[63] J. Shar, T. Obey and T. Cosgrove, Adsorption studies of polyether's- Part1: Adsorption onto hy- drophobic surfaces, Colloid Surf A: Physicochemical and Engineering Aspects 136 (1998) 21–33, DOI:10.1016/S0927-7757(97)00182-9.

[64] E. Leo, B. Brina, F. Forni and M. Vandelli, In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form, Int. J. Pharm. 278 (2004) 133–141, DOI: 10.1016/j.ijpharm.2004.03.002.

[65] U. Bilati, E. Allemann and E. Doelker, Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles, Eur. J. Pharm. Sci. 24 (2005) 67–75; DOI: 10.1016/j.ejps.2004.09.011.

[66] M. Bivas-Benita, S. Romeijn, H. Junginger and G. Borchard, PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium, Eur. J. Pharm. Biopharm. 58 (2004) 1–6; DOI:10.1016/j.ejpb.2004.03.008.

[67] H. Fessi, F. Puisieux, J. Devissaguet, N. Ammoury and S. Benita, Nanocapsule formation by in- terfacial polymer deposition following solvent displacement, Int. J. Pharm. 55 (1989) R1-R4; DOI:10.1016/0378-5173(89)90281-0.

[68] M. Chorny, I. Fishbein, H. D. Danenberg and G. Golomb, Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and re- lease kinetics, J. Control. Release 83 (2002) 389–400; DOI:10.1016/S0168-3659(02)00211-0.

[69] V. Mosqueira, P. Legrand, H. Pinto-Alphandary, F. Puisieux and G. Barratt, Poly (D, L-lactide) nanocapsules prepared by a solvent displacement process: influence of the composition on physicochemical and structural properties, J. Pharm. Sci. 89 (2000) 614–626; DOI: 10.1002/(SICI)1520-6017(200005)89:5<614::AID-JPS7>3.0.CO;2-7.

[70] J. Ren, H. Hong, J. Song and T. Ren, Particle size and distribution of biodegradable poly-D, L-lactide-co-poly(ethylene glycol) block polymer nanoparticles prepared by nanoprecipitation, J. Appl. Polym. Sci. 98 (2005) 1884–1890; DOI: 10.1002/app.22070.

[71] M. Teixeira, M. Alonso, M. Pinto and C. Barbosa, Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3methoxyxanthone, Eur. J. Pharm. Bio- pharm. 59 (2005) 491–500; DOI: 10.1016/j.ejpb.2004.09.002.

[72] M. Tobìo, R. Gref, A. Sanchez, R. Langer and M. Alonso, Stealth PLA-PEG nanoparticles as pro- tein carriers for nasal administration, Pharm. Res. 15 (1998) 276–279; DOI:10.1023/A:1011922 819926.

[73] H. Brittain, D. Bogdanowich, J. DeVincentis, G. Lewen and A. Newman, Physical characteriza- tion of pharmaceutical solids, Pharm. Res. 8 (1991) 963–973. DOI:10.023/A:1015888520352.

[74] M. Hombreiro-Perez, J. Siepmann, C. Zinutti, A. Lamprecht, N. Ubrich, M. Hoffman, R. Bodmeier and P. Maincent, Non-degradable microparticles containing a hydrophilic and/or a li- pophilic drug: preparation, characterization and drug release modeling, J. Control. Release 88 (2003) 413–428; DOI: 10.1016/S0168-3659(03)00030-0.

[75] M. Guyot and F. Fawaz, Nifedipine loaded-polymeric microspheres: preparation and physical characteristics, Int. J. Pharm. 175 (1998) 61–74; DOI:10.1016/S0378-5173(98)00253-1.